Synergistic effects of Endostar combined with β-elemene on malignant ascites in a mouse model

Experimental and Therapeutic Medicine

Volumn 4, Issue 2, 2012, Pages 277-284

  Jiang, Zi Yu ^a   Qin, Shu Kui ^b   Yin, Xiao Jin ^c   Chen, Ya Li ^c   Zhu, Lin ^c  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c Jiangsu Simcere Pharmaceutical Research Institute   (China)

Author keywords

elemene; Antiangiogenesis; Endostar; Malignant ascites; Recombinant human endostatin; Vascular endothelial growth factor

Indexed keywords

BETA ELEMENE; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; RECOMBINANT ENDOSTATIN; SODIUM CHLORIDE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES CELL; BLOOD VESSEL PERMEABILITY; CANCER MODEL; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALIGNANT ASCITES; MOUSE; NONHUMAN; SURVIVAL RATE;

EID: 84862681363     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.583     Document Type: Article

References (22)

1. Garrison RN, Kaelin LD, Galloway RH and Heuser LS: Malignant ascites: clinical and experimental observations. Ann Surg 203: 644-651, 1986.
2. Becker G, Galandi D and Blum HE: Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 42: 589-597, 2006.
3. Tamsma JT, Keizer HJ and Meinders AE: Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited. Ann Oncol 12: 1353-1357, 2001.
4. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
5. Ling Y, Yang Y, Lu N, et al: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361: 79-84, 2007.
6. Wang J, Sun Y, Liu Y, et al: Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 8: 283-290, 2005 (In Chinese).
7. Li Y, Huang XE and Yan PW, et al: Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Asian Pac J Cancer Prev 11: 1119-1123, 2010
8. Jiang Z and Qin S: Study progression of recombinant human endostatin (Endostar) for the treatment of malignant serous effusion. Chinese-German J Clin Oncol 10: 435-441, 2011.
9. Li QQ, Wang G, Huang F, et al: Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumor cells. J Pharm Pharmacol 62: 1018-1027, 2010.
10. Chen W, Lu Y, Wu J, et al: Beta-elemene inhibits melanoma growth and metastasis via suppressing vascular endothelial growth factor-mediated angiogenesis. Cancer Chemother Pharmacol 67: 799-808, 2011.
11. Zhao J, Li QQ, Zou B, et al: In vitro combination characterization of the new anticancer plant drug β-elemene with taxanes against human lung carcinoma. Int J Oncol 31: 241-252, 2007.
12. Wang J, Zhang H and Sun Y: Phase III clinical trial of elemenum emulsion in the management of malignant pleural and peritoneal effusions. Zhonghua Zhong Liu Za Zhi 18: 464-467, 1996 (In Chinese).
13. Kanaoka Y, Maekawa A, Penrose JF, et al: Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C4 synthase. J Biol Chem 276: 22608-22613, 2001.
14. Cao SS and Zhen YS: Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol 24: 181-186, 1989.
15. Zhang J, Wang X and Lu H: Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase. Cancer Lett 260: 127-136, 2008.
16. Senger DR, Galli SJ, Dvorak AM, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983.
17. Zebrowski BK, Liu W, Ramirez K, et al: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6: 373-378, 1999.
18. Luo JC, Toyoda M and Shibuya M: Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 58: 2594-2600, 1998.
19. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
20. Sun XM, Dong WG, Yu BP, et al: Detection of type IV collagenase activity in malignant ascites. World J Gastroenterol 9: 2592-2595, 2003.
21. Hewitson KS, McNeill LA and Schofield CJ: Modulating the hypoxia-inducible factor signaling pathway: applications from cardiovascular disease to cancer. Curr Pharm Des 10: 821-833, 2004.
22. Fujiwara S, Nakagawa K, Harada H, et al: Silencing hypoxia-inducible factor-1α inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int J Oncol 30: 793-802, 2007.